Skip to main content

Table 1 Clinical features and selected laboratory abnormalities of COVID-19 patients with or without Aspergillus infection

From: Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series

VariableAspergillus positive (n = 8)Aspergillus negative (n = 96)P value
Demographics
 Age, mean (SD), years73 (13)53 (15)< 0.001
 Male sex, no. (%)8 (100)54 (56.3)0.02
Underlying disease, no. (%)
 Any7 (87.5)36 (37.5)0.008
 Hypertension7 (87.5)31 (32.3)0.003
 Diabetes mellitus2 (25)11 (11.5)0.262
 Heart disease1 (12.5)6 (6.3)0.439
 COPD2 (25)2 (2.1)0.029
 Cancer0 (0)1 (1.0)1
 Immunodeficiency0 (0)0 (0)
 Chronic kidney disease2 (25)0 (0)0.005
 Pregnancy0 (0)3 (3.1)1
Smoking in the past 1 year, no. (%)2 (25)6 (6.3)0.115
Severe/critical type, no. (%)8 (100)70 (72.9)0.196
Complications, no. (%)
 ARDS4 (50)38 (39.6)0.712
 Shock0 (0)0 (0)
 Liver damage1 (12.5)7 (7.3)0.485
 Acute kidney injury1 (12.5)0 (0)0.077
Treatment, no. (%)
 Mechanical ventilation4 (50)11 (11.5)0.014
 ECMO1 (12.5)3 (3.1)0.278
 CRRT1 (12.5)1 (1.0)0.149
Corticosteroid treatment, no. (%)6 (75)57 (59.4)0.475
 Maximum methylprednisolone equivalent dosage, median (IQR), mg/day70 (5–80)40 (0–60)0.191
Administration of antiviral treatment8 (100)89 (92.7)1
Initial antibiotic treatment, no./total (%)6 (75)46 (47.9)0.269
 3rd-generation cephalosporin0 (0)7 (7.3)1
 Fluoroquinolone3 (37.5)26 (27.1)0.683
 β-Lactamase inhibitors6 (75)17 (17.7)0.001
ICU admission, no./total (%)8 (100)18 (18.8)0